• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for TECFIDERA issued to BIOGEN INC

    3/13/24 9:00:51 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIIB alert in real time by email
    New Drug Application (NDA): 204063
    Company: BIOGEN INC
    • Email
    • Other Important Information from FDA
    • Summary Review

    Products on NDA 204063

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    TECFIDERA DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription AB Yes No
    TECFIDERA DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription AB Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 204063

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    03/27/2013 ORIG-1 Approval Type 1 - New Molecular Entity STANDARD Label (PDF)
    Letter (PDF)
    Review
    Summary Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204063Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000SumR.pdf
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    12/13/2023 SUPPL-32 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204063s032lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204063Orig1s032ltr.pdf
    03/12/2024 SUPPL-31 Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204063s031lbl.pdf
    09/29/2022 SUPPL-30 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204063s028s030lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/204063Orig1s028, s030ltr.pdf
    02/10/2023 SUPPL-29 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204063s029lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204063Orig1s029ltr.pdf
    09/29/2022 SUPPL-28 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204063s028s030lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/204063Orig1s028, s030ltr.pdf
    02/10/2022 SUPPL-27 Labeling-Package Insert Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204063s027lbl.pdf
    01/29/2021 SUPPL-26 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204063s026lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/204063Orig1s026ltr.pdf
    12/11/2019 SUPPL-25 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204063s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/204063Orig1s025ltr.pdf
    07/10/2019 SUPPL-24 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204063s024lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/204063Orig1s024ltr.pdf
    02/05/2020 SUPPL-23 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204063s023lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/204063Orig1s023ltr.pdf
    12/15/2017 SUPPL-20 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204063s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/204063Orig1s020ltr.pdf
    01/19/2017 SUPPL-17 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204063s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/204063Orig1s017ltr.pdf
    12/24/2015 SUPPL-15 Manufacturing (CMC)

    Label is not available on this site.

    02/29/2016 SUPPL-14 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204063s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/204063Orig1s014ltr.pdf
    10/16/2015 SUPPL-13 Manufacturing (CMC)

    Label is not available on this site.

    07/14/2015 SUPPL-12 Manufacturing (CMC)

    Label is not available on this site.

    06/16/2015 SUPPL-11 Manufacturing (CMC)

    Label is not available on this site.

    12/03/2014 SUPPL-10 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204063s003s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204063Orig1s003,s008,s010ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204063Orig1s010.pdf
    11/14/2014 SUPPL-9 Labeling-Container/Carton Labels Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204063Orig1s009ltr.pdf
    12/03/2014 SUPPL-8 Labeling-Package Insert, Labeling-Patient Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204063s003s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204063Orig1s003,s008,s010ltr.pdf
    03/06/2015 SUPPL-6 Manufacturing (CMC)

    Label is not available on this site.

    08/18/2014 SUPPL-5 Manufacturing (CMC)

    Label is not available on this site.

    12/03/2014 SUPPL-3 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204063s003s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204063Orig1s003,s008,s010ltr.pdf
    08/20/2013 SUPPL-2 Manufacturing (CMC)

    Label is not available on this site.

    Labels for NDA 204063

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    03/12/2024 SUPPL-31 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204063s031lbl.pdf
    12/13/2023 SUPPL-32 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204063s032lbl.pdf
    02/10/2023 SUPPL-29 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204063s029lbl.pdf
    09/29/2022 SUPPL-30 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204063s028s030lbl.pdf
    09/29/2022 SUPPL-28 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204063s028s030lbl.pdf
    02/10/2022 SUPPL-27 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204063s027lbl.pdf
    01/29/2021 SUPPL-26 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204063s026lbl.pdf
    02/05/2020 SUPPL-23 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204063s023lbl.pdf
    12/11/2019 SUPPL-25 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204063s025lbl.pdf
    07/10/2019 SUPPL-24 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204063s024lbl.pdf
    12/15/2017 SUPPL-20 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204063s020lbl.pdf
    01/19/2017 SUPPL-17 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204063s017lbl.pdf
    02/29/2016 SUPPL-14 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204063s014lbl.pdf
    12/03/2014 SUPPL-10 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204063s003s008s010lbl.pdf
    12/03/2014 SUPPL-8 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204063s003s008s010lbl.pdf
    12/03/2014 SUPPL-8 Labeling-Patient Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204063s003s008s010lbl.pdf
    12/03/2014 SUPPL-3 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204063s003s008s010lbl.pdf
    03/27/2013 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf

    Therapeutic Equivalents for NDA 204063

    TECFIDERA

    CAPSULE, DELAYED RELEASE;ORAL; 120MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210499 ACCORD HLTHCARE
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210440 ALKEM LABS LTD
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210402 AMNEAL
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210385 AUROBINDO PHARMA
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210305 CIPLA
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210309 GLENMARK PHARMS LTD
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210500 HETERO LABS LTD III
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210226 LUPIN
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210460 MSN
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210531 MYLAN
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210414 PRINSTON INC
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210436 SOLA PHARMS
    DIMETHYL FUMARATE DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210382 TWI PHARMS
    TECFIDERA DIMETHYL FUMARATE 120MG CAPSULE, DELAYED RELEASE;ORAL Prescription Yes AB 204063 BIOGEN INC

    CAPSULE, DELAYED RELEASE;ORAL; 240MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210499 ACCORD HLTHCARE
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210440 ALKEM LABS LTD
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210402 AMNEAL
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210385 AUROBINDO PHARMA
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210305 CIPLA
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210309 GLENMARK PHARMS LTD
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210500 HETERO LABS LTD III
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210226 LUPIN
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210460 MSN
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210531 MYLAN
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210414 PRINSTON INC
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210436 SOLA PHARMS
    DIMETHYL FUMARATE DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription No AB 210382 TWI PHARMS
    TECFIDERA DIMETHYL FUMARATE 240MG CAPSULE, DELAYED RELEASE;ORAL Prescription Yes AB 204063 BIOGEN INC
    Get the next $BIIB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB

    DatePrice TargetRatingAnalyst
    9/25/2025$190.00Buy
    Jefferies
    7/21/2025$142.00Hold
    Truist
    4/28/2025$118.00Buy → Hold
    HSBC Securities
    4/4/2025Buy → Hold
    Argus
    2/11/2025$160.00Mkt Perform
    Bernstein
    1/2/2025$315.00 → $138.00Overweight → Neutral
    Piper Sandler
    12/20/2024$230.00 → $164.00Outperform → Market Perform
    BMO Capital Markets
    12/16/2024$175.00Buy → Hold
    Stifel
    More analyst ratings

    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Biogen with a new price target

    Jefferies initiated coverage of Biogen with a rating of Buy and set a new price target of $190.00

    9/25/25 8:28:11 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on Biogen with a new price target

    Truist resumed coverage of Biogen with a rating of Hold and set a new price target of $142.00

    7/21/25 8:31:03 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Biogen from Buy to Hold and set a new price target of $118.00

    4/28/25 8:32:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

    3/25/24 4:41:37 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Godbout Sean converted options into 26 shares and covered exercise/tax liability with 8 shares, increasing direct ownership by 4% to 495 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    10/6/25 1:00:24 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Head of Development Singhal Priya converted options into 1,669 shares, covered exercise/tax liability with 807 shares and sold $69,045 worth of shares (517 units at $133.55), increasing direct ownership by 6% to 5,772 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    9/2/25 5:56:03 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Head of Global Product Strat. Izzar Rachid sold $300,105 worth of shares (2,223 units at $135.00), decreasing direct ownership by 26% to 6,330 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    7/16/25 5:55:39 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    5/5/25 4:17:10 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/20/24 9:13:26 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    SEC Filings

    View All

    Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOGEN INC. (0000875045) (Filer)

    7/31/25 6:13:54 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Biogen Inc.

    10-Q - BIOGEN INC. (0000875045) (Filer)

    7/31/25 6:05:42 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOGEN INC. (0000875045) (Filer)

    7/7/25 4:10:34 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

    – An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overall clinical status at 3 years in the open-label extension studies reported by clinicians and caregivers in 95% of patients treated with zorevunersen – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced the presentation of longer-term follow-up analyses from the ongoing open-label extension

    10/9/25 4:30:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    Financials

    Live finance-specific insights

    View All

    Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

    Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

    6/25/25 7:30:37 AM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

    Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and

    4/1/25 7:30:00 AM ET
    $BIIB
    $OGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

    Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

    2/18/25 6:00:00 AM ET
    $BIIB
    $PRAX
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Retail: Computer Software & Peripheral Equipment

    $BIIB
    Leadership Updates

    Live Leadership Updates

    View All

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

    BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

    6/3/25 7:00:00 AM ET
    $BIIB
    $TRDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care